your market intelligence analyst
Search Results
19 results
Your search is now limited to «Diabetes Clinical Trials» expert search.
Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept - A Retrospective Cohort Study Christoph Kern,1,2 Johannes Schiefelbein,1 Dun Jack Fu,2 Benedikt Schworm,1 Dawn Sim,2 Tina Herold,1 Siegfried Priglinger,1 Karsten Kortuem1,2 1Department of Ophthalmology, University Hospital LMU, Munich, Germany; 2Moorfields Eye Hospital, London, UKCorrespondence: Christoph KernDepartment of Ophthalmology, University Hospital, LMU Munich, Mathildenstraße 8, Munich 80336, GermanyTel +49 89 4400 53812Email Christoph.kern@med.uni-muenchen.dePurpose: To assess visual and anatomical outcomes of intravitreal aflibercept for clinically significant diabetic macular oedema (DME).Methods: For t.
FeedNavigator (EU) 02/20/2020 08:37
Ascorbic acid (vitamin C) is an important water-soluble vitamin found in many fruits and vegetables. It has well-documented beneficial effects on the human body and is used as a supplement, alone or in combination with other vitamins and minerals. Over recent years, research has focused on possible new therapeutic actions in chronic conditions including periodontal disease (PD). We conducted a systematic review on clinical trials from four databases (PubMed, Clinical Trials, Cochrane, Web of Science) which measured plasmatic/salivary levels of ascorbic acid in PD–diabetes mellitus (DM) association. Six studies were included in our review, three of them analyzing patients with different grades of PD and DM who received vitamin C as a treatme.
FeedNavigator (EU) 02/20/2020 07:11
INTRODUCTION: Despite the beneficial cardiometabolic effects of adiponectin demonstrated in preclinical studies, paradoxically, higher circulating adiponectin concentrations has been found, in epidemiological studies, to be associated with incident cardiovascular events, renal outcomes, as well as mortality, in patients with diabetes.
FeedNavigator (EU) 02/19/2020 10:37
Aims To assess efficacy and safety of fixed‐ratio (1:1) combination insulin glargine and lixisenatide (iGlarLixi) compared to insulin glargine U100 (iGlar), with metformin, in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on basal insulin and oral antidiabetic drugs (OADs.

Personal Care

Household Products

Business Issues


Companies - Public

Companies - Venture Funded

Information Technologies


Job Titles